Seeking Alpha

The huge runup in shares of Inhibitex (INHX +32%) following the announcement of the...

The huge runup in shares of Inhibitex (INHX +32%) following the announcement of the Gilead-Pharmasset deal makes sense to Canaccord Genuity. Analysts with the firm say the premium paid by Gilead (GILD -11.3%) validates the nuc prodrug platform and will "provide a backbone" to the hepatitis C treatment landscape for both INHX and GILD.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs